This study will evaluate the safety of and immune responses to a dendritic cell vaccination for HIV-1 infection. The vaccine will be made from a patient's own cells combined with small fragments of HIV-1 (made synthetically in a laboratory). These cells will be administered back to the patient either into a vein (intravenously) or the skin (subcutaneously).
No linked publications found in PubMed
Inclusion Criteria * HIV-1 infection * Current CD4 count more than 400/mm3 * HIV RNA less than 400 copies/ml * Stable combination antiretroviral therapy for at least 4 weeks prior to study entry * HLA A2.1 (to be tested at screening) Exclusion criteria * Prior HIV vaccine * Systemic steroids or immunosuppressive drugs within 30 days of study entry * Pregnant or breastfeeding